Symptoms and Coping Strategies Among Patients With Implantable Cardioverter Defibrillator

Implantable cardioverter defibrillators (ICDs) are widely used medical devices designed to prevent sudden cardiac death in patients with life-threatening ventricular arrhythmias. Although ICD therapy has significantly improved survival rates in high-risk heart patients, its presence can introduce new physical and psychological challenges that may impact daily life. Patients living with an ICD often report various symptoms such as palpitations, fatigue, chest discomfort, and sleep disturbances. In addition to these physical symptoms, psychological distress such as anxiety, fear of shock, and uncertainty about the future is also commonly observed.

Transitioning to life with an ICD requires not only physiological adaptation but also emotional and behavioral adjustment. How patients perceive the presence of the device and how they cope with it plays a critical role in their overall quality of life. While technological advancements have reduced inappropriate shocks and device-related complications, the psychosocial burden remains significant for many patients. As a result, coping strategies, particularly non-pharmacological approaches, have become essential tools for managing stress associated with ICDs and maintaining psychological balance.

Despite the increasing number of ICD recipients, there remains a gap in the literature regarding the specific symptoms experienced post-implantation and the individual coping mechanisms employed by patients. Investigating these dimensions could provide healthcare providers with insights into the ongoing needs of ICD patients and guide the development of supportive interventions that address both physical symptoms and emotional responses.

This study aims to identify the most common symptoms among ICD patients and investigate the methods they use to cope with these symptoms. By better understanding patient experiences, clinicians can provide more comprehensive and patient-centered care tailored to this unique population.

Inclusion criteria

• Participants were informed about the study and provided informed consent to participate voluntarily,
• Patients who had an ICD implanted at least 3 months prior to the study,
• Patients with no communication difficulties (speak Turkish, no mental retardation),
• Adult patients aged 18 years or older.

Exclusion criteria

• Patients who are unable to provide informed consent regarding the study
• Patients who have undergone ICD implantation less than 3 months prior
• Patients who have difficulty communicating
• Patients under the age of 18
• Patients whose symptoms cannot be directly attributed to the ICD due to serious physical illness